Literature DB >> 24920528

Markers for visceral hypersensitivity in patients with irritable bowel syndrome.

S Ludidi1, Z Mujagic, D Jonkers, D Keszthelyi, M Hesselink, J Kruimel, J Conchillo, A Masclee.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is a heterogenous disorder with visceral hypersensitivity as important hallmark. It is not known whether IBS patients with visceral hypersensitivity have different epidemiological and clinical characteristics compared with IBS patients without visceral hypersensitivity. Aim of our study was to compare in detail a large group of hyper- vs normosensitive IBS patients with respect to epidemiological and clinical characteristics.
METHODS: IBS patients (Rome III criteria) have been recruited for a large-scale cohort study. All patients from this cohort who underwent a rectal barostat procedure were included and allocated based on those with and without visceral hypersensitivity. Patient demographics, and symptoms were collected using questionnaires (GSRS, HADS, SF-36) and a 14-day symptom diary for IBS-related symptoms. A multivariate logistic regression model was used to identify risk markers for having visceral hypersensitivity. KEY
RESULTS: Ninety-five normosensitive and 93 hypersensitive IBS patients participated in this study. Hypersensitive patients had significantly higher scores for GSRS abdominal pain (p < 0.05), indigestion, reflux and constipation syndrome (all p < 0.01), and IBS symptom intensity, discomfort (both p < 0.05) and mean symptom composite score (p < 0.01). Age, female sex, and the use of SSRI medication were significantly different between the normo- and the hypersensitive IBS patients. However, after adjustment for other risk markers, only increasing age was found to be significantly associated with lower odds for having hypersensitivity (OR 0.97 [95% CI: 0.94; 0.99]). CONCLUSIONS & INFERENCES: Apart from more severe symptomatology, hypersensitive IBS patients are characterized by significantly younger age compared with normosensitive IBS patients. The study has been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, NCT00702026).
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  barostat; irritable bowel syndrome; symptoms; visceral hypersensitivity

Mesh:

Year:  2014        PMID: 24920528     DOI: 10.1111/nmo.12365

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  13 in total

1.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

Review 2.  The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments.

Authors:  Mohammad H Farzaei; Roodabeh Bahramsoltani; Mohammad Abdollahi; Roja Rahimi
Journal:  J Neurogastroenterol Motil       Date:  2016-10-30       Impact factor: 4.924

3.  Piezo2: A Candidate Biomarker for Visceral Hypersensitivity in Irritable Bowel Syndrome?

Authors:  Tao Bai; Ying Li; Jing Xia; Yudong Jiang; Lei Zhang; Huan Wang; Wei Qian; Jun Song; Xiaohua Hou
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

4.  Adipose Tissue-Derived Biomarkers of Intestinal Barrier Functions for the Characterization of Diarrhoea-Predominant IBS.

Authors:  Francesco Russo; Guglielmina Chimienti; Giuseppe Riezzo; Michele Linsalata; Benedetta D'Attoma; Caterina Clemente; Antonella Orlando
Journal:  Dis Markers       Date:  2018-11-28       Impact factor: 3.434

5.  Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome.

Authors:  Zsa Zsa R M Weerts; Lisa Vork; Zlatan Mujagic; Daniel Keszthelyi; Martine A M Hesselink; Joanna Kruimel; Carsten Leue; Jean W M Muris; Daisy M A E Jonkers; Ad A M Masclee
Journal:  Neurogastroenterol Motil       Date:  2019-05-22       Impact factor: 3.598

6.  Relationships between psychological state, abuse, somatization and visceral pain sensitivity in irritable bowel syndrome.

Authors:  Cecilia Grinsvall; Hans Törnblom; Jan Tack; Lukas Van Oudenhove; Magnus Simrén
Journal:  United European Gastroenterol J       Date:  2017-06-20       Impact factor: 4.623

7.  A novel biomarker panel for irritable bowel syndrome and the application in the general population.

Authors:  Zlatan Mujagic; Ettje F Tigchelaar; Alexandra Zhernakova; Thomas Ludwig; Javier Ramiro-Garcia; Agnieszka Baranska; Morris A Swertz; Ad A M Masclee; Cisca Wijmenga; Frederik J van Schooten; Agnieszka Smolinska; Daisy M A E Jonkers
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

8.  Isomalto-oligosaccharides ameliorate visceral hyperalgesia with repair damage of ileal epithelial ultrastructure in rats.

Authors:  Weida Wang; Haiwei Xin; Xiucai Fang; Hongtao Dou; Fangyi Liu; Dan Huang; Shaomei Han; Guijun Fei; Liming Zhu; Shenghua Zha; Hong Zhang; Meiyun Ke
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

9.  Depression Promotes the Onset of Irritable Bowel Syndrome through Unique Dysbiosis in Rats.

Authors:  Takeshi Takajo; Kengo Tomita; Hanae Tsuchihashi; Shingo Enomoto; Masaaki Tanichi; Hiroyuki Toda; Yoshikiyo Okada; Hirotaka Furuhashi; Nao Sugihara; Akinori Wada; Kazuki Horiuchi; Kenichi Inaba; Yoshinori Hanawa; Naoki Shibuya; Kazuhiko Shirakabe; Masaaki Higashiyama; Chie Kurihara; Chikako Watanabe; Shunsuke Komoto; Shigeaki Nagao; Katsunori Kimura; Soichiro Miura; Kunio Shimizu; Ryota Hokari
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

10.  Patient-Specific Stress-Abdominal Pain Interaction in Irritable Bowel Syndrome: An Exploratory Experience Sampling Method Study.

Authors:  Lisa Vork; Daniel Keszthelyi; Sander M J van Kuijk; Emilio G Quetglas; Hans Törnblom; Magnus Simrén; Qasim Aziz; Maura Corsetti; Jan Tack; Zlatan Mujagic; Carsten Leue; Joanna W Kruimel; Ad A M Masclee
Journal:  Clin Transl Gastroenterol       Date:  2020-07       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.